BCLI BRAINSTORM CELL THERAPEUTICS INC.

BEARISH Impact: 5/10 EFFECT
Horizon weeks Filed Jun 3, 2026 Processed 11d 22h ago SEC 9999999995-26-001853
IPO/offering going effective
Latest settled — T+1d
BCLI ▲ +2.60% at T+1d
SHORT call ✗ call lost -2.60% · α vs SPY -2.20% · entry $0.7700 → $0.7900
Next anchor: T+5d due 5d ago
Last close $0.7500 (close Jun 12) · +2.60% from $0.7700 entry (call sign-flipped)
Entry anchored
Jun 3, 2026
via day open
T+1d
+2.60%
call -2.60% · α -2.20%
$0.7900
settled 11d ago
T+5d
call — · α —
due 5d ago
T+20d
call — · α —
in 17d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

BrainStorm Cell Therapeutics' S-1 registration statement (File No. 333-296090) was declared effective by the SEC on June 2, 2026, under the 1933 Act. This allows the company to sell securities under the shelf registration, creating potential dilution overhang for existing shareholders.

Actionable Insight

The shelf registration is now effective, meaning BrainStorm can sell shares at any time, creating an overhang of potential dilution. Monitor for a prospectus supplement or 8-K announcing a specific offering — that would crystallize the dilution. The stock's OTC listing and weak analyst consensus (0% bullish) amplify downside risk from any future issuance.

Key Facts

  • Effectiveness date: June 2, 2026
  • SEC File No.: 333-296090
  • Registration type: S-1 (shelf registration)
  • Company is a clinical-stage biotech with no approved products and trades OTC
  • No specific offering size, price, or terms disclosed in the effectiveness notice

Financial Impact

Undisclosed offering size; potential dilution from future share sales under the shelf registration

dilutionshare count

Risk Factors

  • Future share issuance under the shelf could dilute existing holders significantly
  • Clinical-stage biotech with no revenue and OTC listing — limited liquidity and high volatility
  • Historical model calls on BCLI have underperformed (T+20 avg -29.47%), suggesting the stock may not react positively to catalysts

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
0% bullish (6 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001853
Document: 9999999995-26-001853-index.html9999999995-26-001853
Document: 9999999995-26-001853.txt9999999995-26-001853
4 reports for BCLI
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for BCLI — sortable, filterable
Type Now
Jun 3, 2026
12d ago
EFFECT
BEARISH ★ 5/10
$0.7700 $0.7900▼ −2.60%▼ −2.20%$0.7500 (+2.60%)
May 28, 2026
17d ago
8-K
NEUTRAL ★ 3/10
$0.7500 $0.7500· 0.00%▼ −0.26%$0.7500 (0.00%)
May 15, 2026
4w ago
8-K
BEARISH ★ 6/10
$0.6900 $0.7100▼ −2.90%▼ −3.55%$0.7500 (−8.70%)
Mar 31, 2026
10w ago
8-K
BULLISH ★ 8/10
$0.9500 $0.8600▼ −9.47%▼ −9.55%$0.7500 (−21.05%)
Showing 4 of 4

US Market Status

Market Closed — Opens in 4h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access